American Society of Hirudotherapy

Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation

Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Keaton B, Acquah SO, Im Lee Y (2022) · ASAIO Journal

Review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE LowSystematic reviewBivalirudin: drug studies

Study Profile

Design
systematic review and random-effects meta-analysis of 11 observational studies (Embase, Cochrane Central, MEDLINE)
Scope
Bivalirudin anticoagulation in ECMO patients
Main result
Bivalirudin associated with significantly lower short-term mortality (OR 0.71, 95% CI 0.55-0.92, p=0.01, I²=7%) compared with heparin in ECMO patients

Key Findings

  • Mortality signal in favor of bivalirudin (OR 0.71, p=0.01)
  • Low heterogeneity (I²=7%) supports robustness
  • Adds quantitative mortality endpoint to ECMO anticoagulant literature
  • Random-effects model used to account for clinical heterogeneity
  • Calls for prospective RCT confirmation

Limitations

  • All included studies observational
  • Selection bias - bivalirudin often reserved for HIT or bleeding patients
  • Variable anticoagulation monitoring strategies across studies
  • Cannot establish causation
  • Not applicable to whole-leech hirudotherapy

Clinical Implications

Hasegawa 2022 contributes a positive mortality signal to the broader bivalirudin ECMO evidence base. For ASH, the meta-analysis demonstrates how the synthetic thrombin inhibitor pathway generates emerging mortality signals under retrospective synthesis, structurally separate from the K040187 device-leech US clinical practice. The mortality finding warrants RCT confirmation.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.